ResearcherTottori UniversityActive in the last 2 years
Yoshihisa Umekita
Matched on ORCID iD 0000-0002-2846-390X; OpenAlex author ID A5073406408. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 12
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 3 papers
Papers 5
- Identification of TMEM115 as a tumor suppressor gene and clinical prognostic factor that influences TERT expression in pancreatic cancer. Co-author DOI 10.1038/s41598-026-49632-7↗
- Impact of CD73+CD39+ B Cells on Immune Evasion in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18437↗
- Maspin Modulates Malignant Phenotypes Depending on Subcellular Localization in Pancreatic Ductal Adenocarcinoma Cell Lines. Last author DOI 10.3390/cancers18111815↗
- Cytoplasmic-only Expression of Maspin Predicts Unfavorable Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.15032↗
- Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.11.028↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Teruhisa Sakamoto · 4 shared papers, 2020–2026 · strength 0.76
- Paper Identification of TMEM115 as a tumor suppressor gene and clinical prognostic factor that influences TERT expression in … DOI 10.1038/s41598-026-49632-7↗
- Paper Impact of CD73+CD39+ B Cells on Immune Evasion in Pancreatic Cancer. DOI 10.21873/anticanres.18437↗
- Paper Cytoplasmic-only Expression of Maspin Predicts Unfavorable Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.15032↗
- Takuki Yagyu · 2 shared papers, 2026 · strength 0.51
- Hirotoshi Mochida · 1 shared paper, 2026 · strength 0.39
- Masaki Morimoto · 2 shared papers, 2020–2026 · strength 0.34
- Hiroyuki Kugoh · 1 shared paper, 2026 · strength 0.28
- Yu Sakano · 1 shared paper, 2026 · strength 0.28
- Yoshiyuki Fujiwara · 2 shared papers, 2020–2021 · strength 0.25
- Takehiko Hanaki · 2 shared papers, 2020–2021 · strength 0.25
- Yoshiyuki Fujiwara · 1 shared paper, 2026 · strength 0.23
- Mikiya Kishino · 1 shared paper, 2026 · strength 0.23
- Ei Uchinaka · 1 shared paper, 2021 · strength 0.14
- Tatsuya Matsura · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.